E3 ubiquitin ligase based protein degradation (Kymera/GSK)
N/A
Report date: 2025/03/19 20:00:56
NME
Base Information
Drug NameE3 ubiquitin ligase based protein degradation (Kymera/GSK)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcKymera Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A